Accordingly, multivalent MERS-CoV S1A-containing nanoparticles were shown to specifically bind to infection sites in individual hosts: dromedary camel nasal epithelial cells, human type II pneumocytes in the alveolar wall that contains an abundance of α2,3-sialyl type 2 LN and a small amount of α2,3-sialyl-LewisX [19], and pipistrelle bat intestinal epithelial cells.